Glaxo Executive’s Memo Suggested Burying Drug Studies
Authors: Feeley, Jef; Fisk, Margaret
Year: 2009
Company Name: GlaxoSmithKline Plc

[This document has not yet been rated] [You must be signed in as faculty to rate this document]   906 views


GlaxoSmithKline Plc, the world’s second-biggest drugmaker, talked about burying negative studies linking its antidepressant drug Paxil to birth defects, according to a company memo introduced at a trial.

The Philadelphia trial is the first of more than 600 cases alleging that London-based Glaxo knew Paxil caused birth defects and hid those risks to pump up profits.

Search for
Teaching Materials